LOGIN  |  REGISTER
Recursion

Quest Diagnostics to Speak at the William Blair 43rd Annual Growth Stock Conference

June 01, 2023 | Last Trade: US$161.69 0.18 0.11

SECAUCUS, N.J., June 1, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the William Blair 43rd Annual Growth Stock Conference. Sam Samad, Executive Vice President and CFO will discuss recent market developments and trends as well as the company's performance and strategy. The presentation is scheduled for Tuesday, June 6, 2023, at 4:20 p.m. Eastern Time.

The presentation will be webcast live during the conference and will be available on the company's investor relations page which can be accessed at ir.QuestDiagnostics.com. The Q&A breakout session will not be webcast live but will be available as a replay. The archived presentation and Q&A breakout session will both be available within 24 hours after the conclusion of the live event and will remain available until July 4, 2023.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

Assertio

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB